0. DOCID:30498 SCORE: 0.0028699470228185
DOCNO: 15773200
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: M S Aapro MS
AFFILIATION: IMO, Clinique de Genolier, 1272 Genolier. maapro@genolier.net
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Revue médicale suisse.
COUNTRY: Switzerland
TITLE: [Medical oncology]
PUBDATE: 20050101
Progresses in medical oncology seem to be speeding up. New drugs developed these last years have been submitted to comparative trials, and many results lead us to expect improvements in the treatment of patients with solid tumors. Unquestionable in some cancer types, these progresses unfortunately sometimes remain marginal in other fields. Survival benefits are not always well established and, confronted with the exploding costs of medicine, the physician might tend to refrain from using some promising drugs. This review is summarizing results of the most important trials, while trying to present data in a context useful to the clinician.


1. DOCID:29186 SCORE: 0.00278504711287501
DOCNO: 15899635
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: Pascal Eschwege P
AFFILIATION: Service d'Urologie, Hôpital Bicêtre, Faculté de Médecine, Paris-Sud.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Bulletin du cancer.
COUNTRY: France
TITLE: [Cyclooxygenase 2 inhibitors and urologic and gynaecologic cancers]
PUBDATE: 20040501
PGE2 is one of the most important prostaglandin involved in the oncogenesis. PGE2 is found at high concentration level in the most of epithelial cancer. Urologic and gynaecologic cancer express the enzyme which are at the origin of PGE2: cyclooxygenase 2. Cox2 inhibitors present anticancer properties demonstrated in wide varieties of cellular and animal models. Human applications are currently tested in many clinical trials for bladder, prostate and uterine carcinomas.


2. DOCID:26678 SCORE: 0.00262952119721404
DOCNO: 10505166
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: etiology
AUTHOR: B Abboud B
AUTHOR: B Tabchy B
AUTHOR: S Jambart S
AUTHOR: W A Hamad WA
AUTHOR: P Farah P
AFFILIATION: Department of General Surgery, Hôtel Dieu de France, Beirut, Lebanon.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of laryngology and otology.
COUNTRY: ENGLAND
TITLE: Benign disease of the thyroid gland and vocal fold paralysis.
PUBDATE: 19990501
Development of vocal fold paralysis in the presence of thyroid disease is strongly indicative of thyroid cancer, and requires surgical exploration. At the same time, vocal fold paralysis does not relieve the surgeon of his obligation to identify and preserve the recurrent laryngeal nerves, since the cause of the paralysis may be a benign disease, with a fair chance of functional recovery after surgery. We hereby report a case of recurrent laryngeal nerve palsy secondary to a multinodular goitre.


3. DOCID:25591 SCORE: 0.00257111383882182
DOCNO: 11228404
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: immunology
AUTHOR: A N Houghton AN
AUTHOR: J S Gold JS
AUTHOR: N E Blachere NE
AFFILIATION: Memorial Sloan-Kettering Cancer Center and Weill Medical School of Cornell University, 1275 York Avenue, New York, NY 10021, USA. a-houghton@ski.mskcc.org
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in immunology.
COUNTRY: England
TITLE: Immunity against cancer: lessons learned from melanoma.
PUBDATE: 20010401
Most major advances in human cancer immunology and immunotherapy have come from studies in melanoma. We are beginning to understand the immune repertoire of T cells and antibodies that are active against melanoma, with recent glimpses of the CD4(+) T cell repertoire. The view of what the immune system can see is extending to mutations and parts of the genome that are normally invisible.


4. DOCID:25206 SCORE: 0.00255659989392277
DOCNO: 9739758
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Repressor Proteins
DESCRIPTOR: Trans-Activation (Genetics)
QUALIFIER: physiology
QUALIFIER: physiology
AUTHOR: L Rapp L
AUTHOR: J J Chen JJ
AFFILIATION: Department of Dermatology, New England Medical Center, Boston, MA, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Biochimica et biophysica acta.
COUNTRY: NETHERLANDS
TITLE: The papillomavirus E6 proteins.
PUBDATE: 19980801
Specific types of human papillomaviruses (HPV) are strongly associated with the development of cervical cancer. The E6 gene from cancer-related HPVs has exhibited functions in tumorigenesis, regulation of transcription, telomerase, and apoptosis. Cancer-related HPVs E6 proteins bind the tumor suppressor p53 and promotes its degradation through an ubiquitin-dependent pathway. Several additional cellular E6-binding proteins have recently been identified and implicated in playing roles in p53-independent functions of E6.


5. DOCID:31797 SCORE: 0.00248175816333223
DOCNO: 12972703
AUTHOR: C Friedrich C
AUTHOR: G Kolb G
AUTHOR: U Wedding U
AUTHOR: L Pientka L
AFFILIATION: Medizinisch-Geriatrische Klinik, Universitätsklinik, Marienhospital Herne, Germany. christoph.friedrich@ruhr-uni-bochum.de
PUBTYPE: Journal Article
JOURNALTITLE: Onkologie.
COUNTRY: Switzerland
TITLE: Comprehensive geriatric assessment in the elderly cancer patient.
PUBDATE: 20030801
The proportion of older cancer patients is increasing due to demographic and disease-specific reasons. However, this group of patients is severely underrepresented in research and clinical therapy. Limitation in physical and functional capacity with considerable interindividual heterogeneity remains one of the important problems in the treatment decision process. One approach to this problem is the use of a Comprehensive Geriatric Assessment (CGA) to describe and classify these deficits with high validity and reliability. The different domains of CGA are described with special respect to the instruments applied, as CGA has also a key role in the decision process.


6. DOCID:26833 SCORE: 0.00247854331600814
DOCNO: 11908366
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: J J Sciubba JJ
AFFILIATION: Dental and Oral Medicine, Johns Hopkins Medical Center, Baltimore, Maryland, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995)
COUNTRY: United States
TITLE: Oral precancer and cancer: etiology, clinical presentation, diagnosis, and management.
PUBDATE: 20001001
Oral and oropharyngeal cancers represent 3% of all cancers in the United States annually, with nearly 50% of people diagnosed with oral and oropharyngeal cancers dying as a result of the disease. Because the dental practitioner is in an ideal position for recognizing any abnormality of the oral mucosa, he or she is involved in the battle against oral cancer by helping establish the diagnosis at an early stage. This article presents the clinical appearance, explains the origins, and describes steps for the management of oral precancer and cancer.


7. DOCID:26967 SCORE: 0.00247571169252047
DOCNO: 11249682
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Liposomes
QUALIFIER: administration & dosage
AUTHOR: G Gregoriadis G
AFFILIATION: Centre for Drug Delivery Research, School of Pharmacy, University of London, 29-39 Brunswick Square, London, WCIN 1AX, UK. Gregoriadis@cua.ulsop.ac.uk
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: DNA vaccines: a role for liposomes.
PUBDATE: 19990201
Vaccination with attenuated or killed microbes, purified or recombinant subunit proteins and synthetic peptides is often hampered by toxicity, the presence of infectious agents, weak immune responses and prohibiting costs, especially in the developing world. Such problems may be circumvented by genetic immunization, which, by the use of plasmid DNA encoding antigens from bacteria, viruses, protozoa and cancers leads to protective humoral and cell-mediated immunity. This review deals with the background and progress made so far with DNA vaccines and evaluates the role of liposomes in their optimization.


8. DOCID:26985 SCORE: 0.00242012859318354
DOCNO: 9811028
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Surgical Flaps
QUALIFIER: surgery
QUALIFIER: methods
AUTHOR: K Sasaki K
AUTHOR: M Nozaki M
AUTHOR: H Nakazawa H
AUTHOR: Y Kikuchi Y
AUTHOR: T Huang T
AFFILIATION: Department of Plastic and Reconstructive Surgery at Tokyo Women's Medical College, Japan.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Plastic and reconstructive surgery.
COUNTRY: UNITED STATES
TITLE: Reconstruction of a large abdominal wall defect using combined free tensor fasciae latae musculocutaneous flap and anterolateral thigh flap.
PUBDATE: 19981101
A large abdominal wall defect was reconstructed with the use of a flap combining the tensor fasciae latae musculocutaneous flap and the anterolateral thigh flap in four individuals who had undergone extensive abdominal wall resection because of cancer. The flap was harvested as a single combined composite flap and was transferred to the recipient site by means of microvascular surgery. Morbidity was minimal and the outcome was satisfactory in all instances.


9. DOCID:30968 SCORE: 0.00239349188051883
DOCNO: 14605452
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: drug therapy
AUTHOR: J Lehmann J
AUTHOR: M Retz M
AUTHOR: M Hack M
AUTHOR: S Siemer S
AUTHOR: M Stöckle M
AFFILIATION: Klinik für Urologie und Kinderurologie, Universität des Saarlandes, Homburg, Deutschland.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Onkologie.
COUNTRY: Switzerland
TITLE: [Systemic chemotherapy for transitional cell carcinoma of the urothelium]
PUBDATE: 20031001
Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy in the mid eighties of the past century clinically significant response rates as well as prolonged survival has been documented. This review summarizes seven Phase-III trials of systemic chemotherapy for advanced urothelial carcinoma as well as results from adjuvant and neoadjuvant Phase-III trials for muscle-invasive bladder cancer including the most recent reports.


10. DOCID:28700 SCORE: 0.0023574077335153
DOCNO: 12001989
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Apoptosis
QUALIFIER: pathology
AUTHOR: Frederik H Igney FH
AUTHOR: Peter H Krammer PH
AFFILIATION: Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Death and anti-death: tumour resistance to apoptosis.
PUBDATE: 20020401
Every cell in a multicellular organism has the potential to die by apoptosis, but tumour cells often have faulty apoptotic pathways. These defects not only increase tumour mass, but also render the tumour resistant to therapy. So, what are the molecular mechanisms of tumour resistance to apoptosis and how can we use this knowledge to resensitize tumour cells to cancer therapy?


11. DOCID:28512 SCORE: 0.00235732449139475
DOCNO: 12690647
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: secondary
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: Patrick Y Wen PY
AUTHOR: David Schiff D
AFFILIATION: Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, 75 Francis St. Boston, MA 02115, USA. pwen@partners.org
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Neurologic clinics.
COUNTRY: United States
TITLE: Neurologic complications of solid tumors.
PUBDATE: 20030201
This article reviews the neurologic complications of the most common solid tumors, including lung, breast, gastrointestinal, genitourinary, gynecologic, head and neck cancers, melanoma and sarcomas. As systemic therapy improves for many of these tumors, patients are surviving longer and the incidence of neurologic complications is increasing.


12. DOCID:29150 SCORE: 0.00233948744563455
DOCNO: 12470902
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: DNA Methylation
QUALIFIER: genetics
QUALIFIER: metabolism
QUALIFIER: genetics
QUALIFIER: metabolism
AUTHOR: Yasuhito Yuasa Y
AFFILIATION: Department of Molecular Oncology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. yuasa.monc@tmd.ac.jp
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Mechanisms of ageing and development.
COUNTRY: Ireland
TITLE: DNA methylation in cancer and ageing.
PUBDATE: 20021101
Epigenetic gene silencing through DNA methylation is now clearly thought to be one of the important steps in the mechanism underlying tumourigenesis. The methylation of several genes increases with age in normal tissues such as the colon. Methylation related to cancer and ageing may lead to new biomarkers and therapeutic concepts for cancer.


13. DOCID:31313 SCORE: 0.00229541461238227
DOCNO: 12440163
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Maxillofacial Prosthesis Implantation
DESCRIPTOR: Palatal Obturators
DESCRIPTOR: Reconstructive Surgical Procedures
QUALIFIER: surgery
QUALIFIER: surgery
QUALIFIER: surgery
AUTHOR: Kengo Nishimoto K
AUTHOR: Mituaki Iwamoto M
AUTHOR: Atuko Karaki A
AUTHOR: Yasuhiro Nishi Y
AUTHOR: Yasuhiko Morita Y
AUTHOR: Yuichi Kurono Y
AFFILIATION: Department of Otolaryngology, Faculty of Medicine, Kagoshima University, Kagoshima.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Nippon Jibiinkoka Gakkai kaiho.
COUNTRY: Japan
TITLE: [Application of prosthetic replacement for bilateral maxillectomy defect]
PUBDATE: 20021001
A 59-year-old woman with large hard palate cancer underwent surgical resection. We constructed a maxillary prosthesis to be connected to the patient's mandibular denture. Bilateral maxillectomy resulted in total loss of the hard palate and bilateral alveolar and partial loss of the soft palate. A obturator prosthesis was prepared beforehand to fit the surgical cavity. The patient recovered functional speech and swallowing at a relatively early stage, achieving satisfactory cosmetic results.


14. DOCID:30156 SCORE: 0.00229020521048056
DOCNO: 15806096
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: toxicity
QUALIFIER: etiology
AUTHOR: Alistair J Lax AJ
AFFILIATION: Department of Microbiology, Dental Institute, King's College London, Floor 28 Guy's Tower, Guy's Hospital, London SE1 9RT, UK. alistair.lax@kcl.ac.uk
PUBTYPE: Journal Article
JOURNALTITLE: Nature reviews. Microbiology.
COUNTRY: England
TITLE: Opinion: Bacterial toxins and cancer--a case to answer?
PUBDATE: 20050401
Since the discovery that Helicobacter pylori infection leads to gastric cancer, other chronic bacterial infections have been shown to cause cancer. The bacterial and host molecular mechanisms remain unclear. However, many bacteria that cause persistent infections produce toxins that specifically disrupt cellular signalling to perturb the regulation of cell growth or to induce inflammation. Other bacterial toxins directly damage DNA. Such toxins mimic carcinogens and tumour promoters and might represent a paradigm for bacterially induced carcinogenesis.